News

Wilex rises after FDA agreement
Enlarge image

BusinessGermany

Wilex rises after FDA agreement

09.10.2012 - German antibody specialist Wilex AG has reached an agreement with the FDA on the further development for its Redectane diagnostic.

According to Wilex, the US regulatory authority accepted the positive vote of an expert committee regarding the clinical usefulness of the test detecting renal tumours. The FDA however demands a second Phase III trial to confirm the diagnostic performance and safety of Redectane. WILEX assumes that an approval can be expected after successful conclusion of this second trial. Originally, the FDA had suggested to run a complex clinical outcomes study to prove the value of Redectane. Dr Paul Bevan, Head of Research and Development, said “eliminating the need for an outcomes-based study – which in our opinion was not a feasible option - will enable us to move forward with our strategy as the regulatory pathway for marketing approval of this innovative imaging agent is now clear. We are delighted with the result.“ 

Redectane is intended to assist in the detection or exclusion of clear cell RCC during diagnostic workup of an intermediate renal mass. Wilex is already conducting preparatory work for the second trial called REDECT 2 and plans to submit the results to the FDA. German antibody specialist Wilex AG has reached an agreement with the FDA on the further development for its Redectane diagnostic. At the Frankfurt Stock Exchange, Wilex was up more than 5% on Monday.

© laborwelt.de/pd

http://www.european-biotechnology-news.com/news/news/2012-04/wilex-rises-after-fda-agreement.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.36 CHF5.88%
  • MERCK KGAA94.27 EUR2.25%
  • STRATEC BIOMEDICAL46.09 EUR1.97%

FLOP

  • VITA 345.55 EUR-3.48%
  • EVOTEC3.75 EUR-2.60%
  • MOLOGEN5.26 EUR-2.59%

TOP

  • WILEX3.15 EUR57.5%
  • THERAMETRICS0.07 CHF16.7%
  • BASILEA120.00 CHF15.2%

FLOP

  • SANTHERA96.30 CHF-16.6%
  • 4SC0.78 EUR-14.3%
  • MOLOGEN5.26 EUR-13.2%

TOP

  • SANTHERA96.30 CHF2434.2%
  • WILEX3.15 EUR433.9%
  • FORMYCON16.23 EUR100.9%

FLOP

  • CYTOS0.36 CHF-87.8%
  • MOLOGEN5.26 EUR-56.7%
  • BIOFRONTERA1.92 EUR-51.3%

No liability assumed, Date: 02.03.2015